Neuroprotective effects of cardiotrophin-like cytokine on retinal ganglion cells
Standard
Neuroprotective effects of cardiotrophin-like cytokine on retinal ganglion cells. / Schuettauf, Frank; Zurakowski, David; Quinto, Kristine; Varde, Meghana A; Besch, Dorothea; Laties, Alan; Anderson, Ralph; Wen, Rong.
In: GRAEF ARCH CLIN EXP, Vol. 243, No. 10, 10.2005, p. 1036-42.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Neuroprotective effects of cardiotrophin-like cytokine on retinal ganglion cells
AU - Schuettauf, Frank
AU - Zurakowski, David
AU - Quinto, Kristine
AU - Varde, Meghana A
AU - Besch, Dorothea
AU - Laties, Alan
AU - Anderson, Ralph
AU - Wen, Rong
PY - 2005/10
Y1 - 2005/10
N2 - BACKGROUND: Premature neuronal cell death is a feature of numerous central nervous system and eye diseases, including glaucoma. Neurons (including retinal ganglion cells, RGCs) are protected by several neurotrophic factors, among those the IL-6 family of cytokines. Lately, a novel member of the IL-6 family of cytokines has been identified and cloned. This cytokine is known as novel neurotrophin-1/B-cell-stimulating factor-3 (NNT-1/BSF-3) or cardiotrophin-like cytokine (CLC). It shows neurotrophic as well as B-cell stimulatory effects.METHODS: In this study, the neuroprotective properties of CLC on RGC loss in vivo were investigated.RESULTS: CLC significantly protected RGCs from degeneration in both chosen models of retinal neuronal damage: optic nerve crush (P<0.01) and N-methyl-D-aspartate (NMDA) injection (P<0.001).CONCLUSIONS: CLC shows neuroprotective effects on RGCs in vivo and might be a treatment option for chronic neurodegenerative eye diseases such as glaucoma. Clinical feasibility for the substance requires further investigation since the immunomodulatory and possible adverse effects have not yet been thoroughly characterized.
AB - BACKGROUND: Premature neuronal cell death is a feature of numerous central nervous system and eye diseases, including glaucoma. Neurons (including retinal ganglion cells, RGCs) are protected by several neurotrophic factors, among those the IL-6 family of cytokines. Lately, a novel member of the IL-6 family of cytokines has been identified and cloned. This cytokine is known as novel neurotrophin-1/B-cell-stimulating factor-3 (NNT-1/BSF-3) or cardiotrophin-like cytokine (CLC). It shows neurotrophic as well as B-cell stimulatory effects.METHODS: In this study, the neuroprotective properties of CLC on RGC loss in vivo were investigated.RESULTS: CLC significantly protected RGCs from degeneration in both chosen models of retinal neuronal damage: optic nerve crush (P<0.01) and N-methyl-D-aspartate (NMDA) injection (P<0.001).CONCLUSIONS: CLC shows neuroprotective effects on RGCs in vivo and might be a treatment option for chronic neurodegenerative eye diseases such as glaucoma. Clinical feasibility for the substance requires further investigation since the immunomodulatory and possible adverse effects have not yet been thoroughly characterized.
KW - Animals
KW - Cell Count
KW - Cell Survival/drug effects
KW - Cytokines/therapeutic use
KW - Disease Models, Animal
KW - Female
KW - Follow-Up Studies
KW - Injections
KW - Macular Degeneration/chemically induced
KW - N-Methylaspartate/administration & dosage
KW - Rats
KW - Rats, Long-Evans
KW - Retinal Ganglion Cells/drug effects
KW - Treatment Outcome
KW - Vitreous Body
U2 - 10.1007/s00417-005-1152-7
DO - 10.1007/s00417-005-1152-7
M3 - SCORING: Journal article
C2 - 15838664
VL - 243
SP - 1036
EP - 1042
JO - GRAEF ARCH CLIN EXP
JF - GRAEF ARCH CLIN EXP
SN - 0721-832X
IS - 10
ER -
